Physician profile
John L Berk
NPI 1407831258
$33,076.00
in general payments reported to CMS, 2019-2025
9 companies · $19.48 in 2025
The $19.48 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,576 · 2020: $165 · 2021: $593 · 2022: $1,776 · 2023: $25K · 2024: $375 · 2025: $19.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,793.00 |
| Food and Beverage | $173.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19,071.02 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $4,020.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $3,912.67 | 2022-2023 | |
| Akcea Therapeutics, INC. | $2,518.31 | 2019 | |
| Merck Sharp & Dohme LLC | $1,620.00 | 2019-2024 | |
| Astrazeneca Uk Limited | $1,000.00 | 2023 | |
| Pfizer INC. | $934.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Berk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.